Cytek Biosciences, Inc.

NASDAQ:CTKB

Medical - Devices

Healthcare
$5.92 -2.64%

-$0.11 today

Market cap
$774.24M
Beta
1.19
P/E (TTM)
-6.7
EPS (TTM)
-$0.57
52W Low $2.90High $6.18

Volume 1.05M

Average 0.88M

CTKB Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Cytek Biosciences, Inc.NASDAQ: CTKB

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income grows, but more slowly than its trailing trend

Q1 FY2026 net income of $18.87M (cash outflow) rose 65.5% year over year, behind the +557.6% change in trailing-twelve-month net income. Sequentially, it fell 57.2% from the prior quarter.

Context

  • Net income amounted to 33.0% of revenue in FY2025, up 30.0 pp from a year earlier.
  • Net income increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 2 analysts of -$36.59M (-45.0%) for the fiscal year ending Dec 2026, a slowdown from the +1005.3% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$18.87M-57.2% QoQ
Last fiscal yearDec 2025
-$66.54M+1005.3% YoY
LTMMar 2026
-$74M+557.6% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+65.5%+117.9%+52.5 pp
1 year+1005.3%-45.0%-1050.3 pp
3-year CAGR—-40.4%—
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
(66.54M) USD
Year-over-year change
-1005.3%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How CTKB compares with its peers on the latest reported figures

  • CTKB's LTM Mar 2026 net income of $74M is the 5th largest of the 6 companies compared; the peer median is $65.8M.
  • Its year-over-year change of +557.6% is the highest of 6, against a peer median of +18.0%.
  • Net income amounts to 36.2% of revenue for CTKB, versus a peer median of 12.2%.
CTKB Competitors Peer median
Net Income for CTKB and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AAgilent Technologies, Inc.LTM Jul 2026$1.44B +18.0%-29.8%19.5%
BIOBio-Rad Laboratories, Inc.LTM Jun 2026$162.3M +36.7%—6.3%
LABStandard BioTools Inc.LTM Mar 2026$78.21M +158.9%-26.7%90.7%
TXG10x Genomics, Inc.LTM Jun 2026$75.13M -11.2%-36.0%12.2%
CTKBCytek Biosciences, Inc.LTM Mar 2026$74M +557.6%—36.2%
BRKRBruker CorporationLTM Jun 2026$65.8M -187.5%—1.9%
Peer median (excluding CTKB) $65.8M+18.0%-29.8%12.2%

Competitors are the stored peer set for CTKB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income3.03M2.48M(12.15M)(6.02M)(66.54M)
Depreciation & Amortization1.24M5.66M9.23M10.49M11.98M
Deferred Income Tax000(2.89M)33.56M
Stock-Based Compensation6.59M16.6M22.05M26.85M24.59M
Change in Working Capital(8.65M)(39.93M)(10.51M)7.71M(4.79M)
Accounts Receivables(12.37M)(19.74M)(7.33M)(5.43M)368K
Inventory(7.07M)(17.65M)4.29M14.76M(5.24M)
Accounts Payables(256K)1.86M(1.78M)2.58M448K
Other Working Capital11.05M(4.39M)(5.68M)(4.2M)(366K)
Other Non-Cash Items2.42M2.96M(3.34M)(10.77M)(3.47M)
Operating Cash Flow4.63M(12.23M)5.28M25.38M(4.69M)
Capital Expenditures(4.36M)(9.87M)(4.83M)(3.53M)(4.08M)
Acquisitions (Net)(16.63M)0(45.13M)(471K)252K
Purchases of Investments0(46.04M)(175.94M)(274.06M)(278.16M)
Sales of Investments00132M195M292.21M
Other Investing Activities0(120K)(179K)84K(107K)
Investing Cash Flow(20.99M)(55.91M)(93.89M)(82.97M)10.12M
Debt Repayment(2.77M)2.93M(565K)3.62M837K
Common Stock Issued215.69M2.79M001.47M
Common Stock Repurchased00(44.15M)(21.61M)(15.07M)
Dividends Paid00000
Other Financing Activities642K(209K)2.9M2.17M(669K)
Financing Cash Flow213.56M5.51M(41.81M)(15.82M)(13.43M)
Effect of Forex Changes1.3M(2.49M)(1.45M)4.53M109K
Net Change in Cash198.5M(65.12M)(131.87M)(68.89M)(7.89M)
Free Cash Flow266K(22.1M)454K21.85M(8.77M)

Cytek Biosciences, Inc.

NASDAQ:CTKB

Intrinsic Alpha fair value

Locked

Current Price

$5.92

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.